Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
Subscribe To Our Newsletter & Stay Updated